Research Article

You have full text access to this OnlineOpen article

The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial

  1. Chung-E Tseng1,*,
  2. Jill P. Buyon1,†,
  3. Mimi Kim2,
  4. H. Michael Belmont1,
  5. Meggan Mackay2,
  6. Betty Diamond2,
  7. Galina Marder3,
  8. Pamela Rosenthal1,
  9. Kathleen Haines1,
  10. Virginia Ilie1,
  11. Steven B. Abramson1

Article first published online: 30 OCT 2006

DOI: 10.1002/art.22198

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 11, pages 3623–3632, November 2006

Additional Information

How to Cite

Tseng, C.-E., Buyon, J. P., Kim, M., Belmont, H. M., Mackay, M., Diamond, B., Marder, G., Rosenthal, P., Haines, K., Ilie, V. and Abramson, S. B. (2006), The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 54: 3623–3632. doi: 10.1002/art.22198

Author Information

  1. 1

    New York University School of Medicine, Hospital for Joint Diseases, New York, New York

  2. 2

    Albert Einstein College of Medicine of Yeshiva University, Bronx, New York

  3. 3

    Long Island Jewish Health System, New Hyde Park, New York

  1. †

    Dr. Buyon has received consulting fees and/or honoraria from Amgen, Aspreva, Bristol-Myers Squibb, Coley, Genentech Pharmaceutical, Human Genome Science, La Jolla Pharmaceutical, Pfizer, and Johnson & Johnson (less than $10,000 each) and has provided expert testimony for Grossman and Roth Attorneys-at-Law on one occasion in 2004.

*Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003

Publication History

  1. Issue published online: 30 OCT 2006
  2. Article first published online: 30 OCT 2006
  3. Manuscript Accepted: 2 AUG 2006
  4. Manuscript Received: 7 NOV 2005

Funded by

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Grant Number: NIAMS-026
  • NIH. Grant Number: NIH R01-AR-44690

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (103K)

REFERENCES

  • 1
    Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-year prospective study. Rheumatology (Oxford) 2004; 43: 1039–44.
  • 2
    Gladman D, Ginzler E, Goldsmith C, Liang M, Urowitz M, Bacon P, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol 1992; 19: 1820–1.
  • 3
    Gripenberg M, Helve T. Outcome of systemic lupus erythematosus: a study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations. Scand J Rheumatol 1991; 20: 104–9.
  • 4
    Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti–double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990; 33: 634–43.
    Direct Link:
  • 5
    Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996; 39: 370–8.
    Direct Link:
  • 6
    Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595–9.
  • 7
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 8
    Buyon JP, Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953–62.
  • 9
    Andersen P, Gill R. Cox's regression model for counting processes: a large sample study. Ann Statistics 1982; 10: 1100–20.
  • 10
    Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979; 66: 210–5.
  • 11
    Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278: 533–8.
  • 12
    Lightfoot RW, Redecha PB, Levasanos N. Longitudinal studies of anti-DNA antibody levels in SLE. Scand J Rheumatol Suppl 1975; 11: 52–8.
  • 13
    Davis P, Percy JS, Russel AS. Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis 1977: 36: 157–9.
  • 14
    Miniter MF, Stollar BD, Agnello V. Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 959–68.
    Direct Link:
  • 15
    Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TW. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 226–35.
    Direct Link:
  • 16
    Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus. Medicine (Baltimore) 1981; 60: 208–17.
  • 17
    Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long-term observation. Ann Rheum Dis 1997; 56: 661–6.
  • 18
    Ho A, Magder LS, Barr SG, Petri M. Decreases in anti–double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342–9.
    Direct Link:
  • 19
    Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12: 535–8.
  • 20
    Buyon JP, Shadick N, Berkman R, Hopkins P, Dalton J, Weissmann G, et al. Surface expression of gp165/95, the complement receptor CR3, as a marker of disease activity in systemic lupus erythematosus. Clin Immunol Immunopathol 1988; 46: 141–9.
  • 21
    Molad Y, Buyon J, Anderson DC, Abramson SB, Cronstein BN. Intravascular neutrophil (PMN) activation in SLE: dissociation between increased CD11b/CD18 (CR3) and decreased L-selectin (LS) expression on neutrophils (PMNS) [abstract]. Arthritis Rheum 1992; 35 Suppl 9: S192.
  • 22
    Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Shwartzman phenomenon revisited. Arthritis Rheum 1994; 3: 376–83.
    Direct Link:
  • 23
    Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1810–6.
    Direct Link:
  • 24
    Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001; 44: 1203–8.
    Direct Link:
  • 25
    Lange K, Wasserman E, Slobody LB. Significance of serum complement levels for diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Intern Med 1960; 53: 636–46.
  • 26
    Ruddy S, Carpenter CB, Chin KW, Knostman JN, Soter NA, Gotze O, et al. Human complement metabolism: an analysis of 144 studies. Medicine (Baltimore) 1975; 54: 165–78.
  • 27
    Alper CA, Rosen F. Studies of the in vitro behavior of human C3 in normal subjects and patients. J Clin Invest 1967; 46: 2021–34.
  • 28
    Sliwinski AJ, Zvaifler NJ. Decreased synthesis of the third component (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol 1972; 11: 21–9.
  • 29
    Moulds JL, Warner NB, Arnett FC. Quantitative and antigenic differences in complement component C4 between American blacks and whites. Complement Inflamm 1991; 8: 281–7.
  • 30
    Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, et al. Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986; 29: 1085–9.
    Direct Link:
  • 31
    Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632–41.
    Direct Link:
  • 32
    Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 1028–37.
    Direct Link:
  • 33
    Abramson S, Belmont HM, Hopkins P, Buyon J, Winchester R, Weissmann G. Complement activation and vascular injury in systemic lupus erythematosus. J Rheumatol 1987; 14 Suppl 13: 43–6.
  • 34
    Abramson SB, Buyon JP. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol 1992; 28: 183–7.
  • 35
    Buyon J, Tamerius J, Ordica S, Young B, Abramson S. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992; 35: 55–61.
    Direct Link:
  • 36
    Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Eng J Med 1985; 312: 1594–9.
  • 37
    Kerr LD, Adelsberg BR, Schulman P, Spiera H. Factor B activation products in patients with systemic lupus erythematosus: a marker of severe disease activity. Arthritis Rheum 1989; 32: 1406–13.
    Direct Link:
  • 38
    Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39: 1178–88.
    Direct Link:
  • 39
    Nagy G, Brozik M, Varga L, Fust G, Kirschfink M, Kiss E, et al. Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 2000; 9: 19–25.
  • 40
    Liu C, Ahearn JM, Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep 2004; 6: 85–8.
  • 41
    Abramson SB, Belmont HM. SLE: mechanism of vascular injury [review]. Hosp Pract (Minneapolis) 1998; 33: 107–10, 113–4, 119–22.
  • 42
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlate of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406.
View Full Article (HTML) Get PDF (103K)